HK Stock MarketDetailed Quotes

02162 KEYMED BIO-B

Watchlist
  • 40.400
  • +0.850+2.15%
Not Open Nov 27 16:08 CST
11.30BMarket Cap-13883P/E (TTM)

KEYMED BIO-B Key Stats

All
YOY yoy
Hide blank lines yoy
(Q6)Jun 30, 2024
(FY)Dec 31, 2023
(Q6)Jun 30, 2023
(FY)Dec 31, 2022
(Q6)Jun 30, 2022
(FY)Dec 31, 2021
(Q6)Jun 30, 2021
(FY)Dec 31, 2020
(FY)Dec 31, 2019
Turnover
-83.28%54.68M
253.87%354.1M
227.12%327.12M
-9.26%100.06M
--100M
--110.27M
----
----
----
Operating income
-83.28%54.68M
253.87%354.1M
227.12%327.12M
-9.26%100.06M
100M
110.27M
Cost of sales
75.12%-3.74M
-1,326.62%-36.88M
-491.92%-15.02M
84.97%-2.59M
---2.54M
---17.2M
----
----
----
Operating expenses
75.12%-3.74M
-1,326.62%-36.88M
-491.92%-15.02M
84.97%-2.59M
-2.54M
-17.2M
Gross profit
-83.68%50.95M
225.42%317.22M
220.23%312.11M
4.74%97.48M
97.46M
93.07M
Selling expenses
---23.25M
----
----
----
----
----
----
----
----
Administrative expenses
-9.20%-89.95M
-32.18%-177.01M
-61.36%-82.37M
-44.84%-133.91M
-90.22%-51.05M
-329.06%-92.45M
---26.84M
-42.16%-21.55M
---15.16M
Research and development expenses
-32.54%-331.03M
-17.52%-596.28M
-52.28%-249.76M
-41.66%-507.37M
14.16%-164.01M
-181.13%-358.16M
---191.06M
-96.57%-127.4M
---64.81M
Revaluation surplus
----
----
----
----
----
-399.70%-3.48B
---3.4B
-616.44%-696.47M
---97.21M
-Changes in the fair value of other assets
----
----
----
----
----
-399.70%-3.48B
---3.4B
-616.44%-696.47M
---97.21M
Operating interest expense
----
----
----
----
77.97%-1.33M
---11.13M
---6.04M
----
----
Special items of operating profit
-7.90%73.31M
-52.81%121.89M
-38.89%79.6M
701.51%258.32M
518.93%130.26M
-205.05%-42.95M
--21.05M
166.36%40.88M
--15.35M
Operating profit
-637.05%-319.96M
-17.06%-334.18M
425.61%59.58M
92.66%-285.49M
100.31%11.34M
-383.74%-3.89B
-3.6B
-397.14%-804.54M
-161.84M
Financing cost
5.07%-8.86M
-105.54%-17.26M
---9.34M
---8.4M
----
----
----
-152.05%-14.31M
---5.68M
Share of profit from joint venture company
19.03%-1.7M
51.11%-4.75M
76.20%-2.1M
-1,250.63%-9.71M
---8.81M
---719K
----
----
----
Special items of earning before tax
----
----
----
----
----
----
---27.75M
----
----
Earning before tax
-786.52%-330.52M
-17.32%-356.19M
1,807.49%48.15M
92.20%-303.6M
100.07%2.52M
-375.38%-3.89B
-3.63B
-388.83%-818.85M
-167.51M
Tax
---6.08M
---1.6M
----
----
----
----
----
----
----
After-tax profit from continuing operations
-799.14%-336.6M
-17.85%-357.79M
1,807.49%48.15M
92.20%-303.6M
100.07%2.52M
-375.38%-3.89B
-3.63B
-388.83%-818.85M
-167.51M
Earning after tax
-799.14%-336.6M
-17.85%-357.79M
1,807.49%48.15M
92.20%-303.6M
100.07%2.52M
-375.38%-3.89B
-3.63B
-388.83%-818.85M
-167.51M
Minority profit
-87.95%142K
-65.21%1.57M
140.20%1.18M
184.88%4.52M
-51.73%-2.93M
-1,908.68%-5.32M
---1.93M
---265K
----
Profit attributable to shareholders
-816.98%-336.75M
-16.63%-359.36M
761.15%46.97M
92.07%-308.12M
100.15%5.45M
-374.88%-3.89B
-3.63B
-388.67%-818.58M
-167.51M
Basic earnings per share
-816.67%-1.29
-16.10%-1.37
765.38%0.18
95.12%-1.18
100.04%0.0208
-98.11%-24.17
-54.08
-12.2
Diluted earnings per share
-816.67%-1.29
-16.10%-1.37
782.35%0.18
95.12%-1.18
100.04%0.0204
-98.11%-24.17
-54.08
-12.2
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
IAS
IAS
IAS
IAS
IAS
IAS
IAS
IAS
IAS
Audit Opinions
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
Unqualified Opinion
Auditor
--
Ernst & Young
--
Ernst & Young
--
Ernst & Young
--
Ernst & Young
Ernst & Young
(Q6)Jun 30, 2024(FY)Dec 31, 2023(Q6)Jun 30, 2023(FY)Dec 31, 2022(Q6)Jun 30, 2022(FY)Dec 31, 2021(Q6)Jun 30, 2021(FY)Dec 31, 2020(FY)Dec 31, 2019
Turnover -83.28%54.68M253.87%354.1M227.12%327.12M-9.26%100.06M--100M--110.27M------------
Operating income -83.28%54.68M253.87%354.1M227.12%327.12M-9.26%100.06M100M110.27M
Cost of sales 75.12%-3.74M-1,326.62%-36.88M-491.92%-15.02M84.97%-2.59M---2.54M---17.2M------------
Operating expenses 75.12%-3.74M-1,326.62%-36.88M-491.92%-15.02M84.97%-2.59M-2.54M-17.2M
Gross profit -83.68%50.95M225.42%317.22M220.23%312.11M4.74%97.48M97.46M93.07M
Selling expenses ---23.25M--------------------------------
Administrative expenses -9.20%-89.95M-32.18%-177.01M-61.36%-82.37M-44.84%-133.91M-90.22%-51.05M-329.06%-92.45M---26.84M-42.16%-21.55M---15.16M
Research and development expenses -32.54%-331.03M-17.52%-596.28M-52.28%-249.76M-41.66%-507.37M14.16%-164.01M-181.13%-358.16M---191.06M-96.57%-127.4M---64.81M
Revaluation surplus ---------------------399.70%-3.48B---3.4B-616.44%-696.47M---97.21M
-Changes in the fair value of other assets ---------------------399.70%-3.48B---3.4B-616.44%-696.47M---97.21M
Operating interest expense ----------------77.97%-1.33M---11.13M---6.04M--------
Special items of operating profit -7.90%73.31M-52.81%121.89M-38.89%79.6M701.51%258.32M518.93%130.26M-205.05%-42.95M--21.05M166.36%40.88M--15.35M
Operating profit -637.05%-319.96M-17.06%-334.18M425.61%59.58M92.66%-285.49M100.31%11.34M-383.74%-3.89B-3.6B-397.14%-804.54M-161.84M
Financing cost 5.07%-8.86M-105.54%-17.26M---9.34M---8.4M-------------152.05%-14.31M---5.68M
Share of profit from joint venture company 19.03%-1.7M51.11%-4.75M76.20%-2.1M-1,250.63%-9.71M---8.81M---719K------------
Special items of earning before tax ---------------------------27.75M--------
Earning before tax -786.52%-330.52M-17.32%-356.19M1,807.49%48.15M92.20%-303.6M100.07%2.52M-375.38%-3.89B-3.63B-388.83%-818.85M-167.51M
Tax ---6.08M---1.6M----------------------------
After-tax profit from continuing operations -799.14%-336.6M-17.85%-357.79M1,807.49%48.15M92.20%-303.6M100.07%2.52M-375.38%-3.89B-3.63B-388.83%-818.85M-167.51M
Earning after tax -799.14%-336.6M-17.85%-357.79M1,807.49%48.15M92.20%-303.6M100.07%2.52M-375.38%-3.89B-3.63B-388.83%-818.85M-167.51M
Minority profit -87.95%142K-65.21%1.57M140.20%1.18M184.88%4.52M-51.73%-2.93M-1,908.68%-5.32M---1.93M---265K----
Profit attributable to shareholders -816.98%-336.75M-16.63%-359.36M761.15%46.97M92.07%-308.12M100.15%5.45M-374.88%-3.89B-3.63B-388.67%-818.58M-167.51M
Basic earnings per share -816.67%-1.29-16.10%-1.37765.38%0.1895.12%-1.18100.04%0.0208-98.11%-24.17-54.08-12.2
Diluted earnings per share -816.67%-1.29-16.10%-1.37782.35%0.1895.12%-1.18100.04%0.0204-98.11%-24.17-54.08-12.2
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards IASIASIASIASIASIASIASIASIAS
Audit Opinions --Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified OpinionUnqualified Opinion
Auditor --Ernst & Young--Ernst & Young--Ernst & Young--Ernst & YoungErnst & Young

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data